Experimental CAR T therapy targets solid tumour cancer cells
Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
List view / Grid view
Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
The team used cryogenic electron microscopy (cryo-EM) to show how the 10E8 antibody interacts with the HIV’s fusion protein to neutralise the virus.
26 June 2020 | By Tecan
This webinar described the recent efforts to identify small molecule therapeutics for the treatment of SARS-CoV-2 infection and COVID-19 disease.
Learn why measuring binding affinity is key to helping you decide the next steps in your research and what technologies are available to measure it.
An antibody with high neutralising potency against SARS-CoV-2 that binds to the N terminal domain of the Spike protein has been identified by a team researching COVID-19 therapeutics.
Immuno-oncology (IO) is increasingly prized as an effective therapy in cancer management.
Researchers who screened 136 broad-spectrum antivirals identified six with the most activity against COVID-19 and an optimum combination of two to fight the virus.
Researchers have proposed a cocktail of two antibodies which they say could provide an effective therapy for COVID-19 patients.
Newly discovered antibodies found in the blood of recovered COVID-19 patients could provide robust protection against SARS-CoV-2, say researchers.
Learn how to measure protein stability, why it’s important, and what the key technologies are available to measure it.
A result is only as good as the sample preparation that preceded it.
ESHG 2019: Automated sample preparation using magnetic bead technology and KingFisher instruments.
Automated detection and isolation of pathogens for multiple samples types.
New opportunities for liquid biopsy: At automated workflow for isolating circulating tumor cells using KingFisher instruments.
Pre-clinical testing of the COVIDTRAP™ (STI-4398) protein and STI-1499 antibody reveal they can inhibit SARS-CoV-2 from infecting cells.